COVID-19 “Round 2” – Findings & way forward (Kearney)

Preparing for a potential second COVID-19 wave. Joint statement by Medicines for Europe and EFPIA with Kearney

LESSONS LEARNED FROM COVID-19 – POLICY PAPER

Physicians recognised potential of Value Added Medicines

Position Paper. Reference safety information: challenges to the generic industry due to labelling harmonisation issues among different Member States

Questions and answers on regulatory expectations for medicinal products for human use during the COVID-19 pandemic

Why is Now the Right Time to Modernise the Eu Variations System?

Medicines Shortages: Causes and Recommendations

AMR Industry Alliance 2020 Progress Report

Medicines for Europe Code of Conduct

OPEN